A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-0976 or Fenofibrate in Subjects With Normal and Impaired Hepatic Function
Latest Information Update: 18 Dec 2020
At a glance
- Drugs Firsocostat (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Gilead Sciences
- 25 Feb 2019 Planned number of patients changed from 60 to 80.
- 24 Dec 2018 Planned End Date changed from 1 Aug 2018 to 1 May 2019.
- 24 Dec 2018 Planned primary completion date changed from 1 Aug 2018 to 1 May 2019.